Clinical Trial

QuantaFlo HD Clinical Validation Study

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 23, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary aim of this validation protocol is to assess cardiovascular function through transthoracic echocardiography ("Echo") measurements and the QuantaFlo HD test measuring blood flow at the finger during a forced expiration ("FE"). The study examines whether Echo-measured GLS values greater than -16% correlate with abnormal responses during FE as measured by QuantaFlo HD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-20.
Trial Details
NCT Number NCT07219693
Lead Sponsor Semler Scientific
Conditions To Assess Cardiovascular Function
Enrollment 600 participants
Start Date 2025-08-21
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-23